Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

BACKGROUND: The activity of palbociclib as a single agent in advanced breast cancer has not been extensively studied, with the only available clinical data limited to heavily pretreated patients. Preclinical data suggests palbociclib may partially reverse endocrine resistance, though this hypothesis...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Ann Oncol
Główni autorzy: Malorni, L, Curigliano, G, Minisini, A M, Cinieri, S, Tondini, C A, D’Hollander, K, Arpino, G, Bernardo, A, Martignetti, A, Criscitiello, C, Puglisi, F, Pestrin, M, Sanna, G, Moretti, E, Risi, E, Biagioni, C, McCartney, A, Boni, L, Buyse, M, Migliaccio, I, Biganzoli, L, Di Leo, A
Format: Artigo
Język:Inglês
Wydane: Oxford University Press 2018
Hasła przedmiotowe:
Original Articles
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6454527/
https://ncbi.nlm.nih.gov/pubmed/29893790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy214
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy